Katell Delanoë
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Katell Delanoë has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Erwan Salaun
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, QC G1C 4G5, Canada
2 shared publications - Nancy Côté
Institut universitaire de cardiologie et de pneumologie de Québec (Quebec Heart and Lung Institute), Université Laval, Québec City, Quebec, Canada (Z.L., B.Z., E.S., N.C., P.P., M.-A.C.).
2 shared publications - Philippe Pibarot
Université Laval
2 shared publications - Régis Rieu
Faculté des Sciences Médicales et Paramédicales, Aix-Marseille Université, LBA UMR T24, 13015 Marseille, France
2 shared publications - Viktória Stanová
Institut Universitaire de Cardiologie et de Pneumologie de Québec Université Laval Québec Canada
2 shared publications Erwan Salaun
1 shared publication
Latest Publications
- Open Access
- 7 April 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (4) , 397
Advanced Silicon Modeling of Native Mitral Valve Physiology: A New Standard for Device and Procedure Testing
Mitral valve regurgitation is among the most prevalent valvular heart diseases and increases with age. Percutaneous therapy has emerged for the management of mitral regurgitation in high surgical risk patients. However, the long-term consequences of these interventions are still not fully understood due to their novelty and the difficulty of developing a strategy specific to the patient’s anatomy and/or pathology. To optimize these outcomes, an in vitro patient-specific approach could provide important insights for the most suitable strategy to use according to the patient profile. To ensure the reliability of this in vitro approach, the aim of this study was to reproduce the physiological behavior of the healthy native mitral valve for future applications. To do so, different silicon combinations reproducing the physiological anatomy of a healthy mitral valve were developed and tested under physiological hemodynamic conditions in a cardiac simulator. The hemodynamic and biomechanical behaviors of each mitral valve model were analyzed and compared to the physiological values provided in the literature. This study identified EcoFlex 00-50 and DragonSkin 10 (Smooth-On Inc., Easton, PA, USA) as the optimal silicon combination resulting in physiological strain values and hemodynamic parameters. These findings could be useful for future patient-specific applications, helping in the optimization of percutaneous mitral valve therapy.
- 7 April 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (4) , 397
Open AccessAdvanced Silicon Modeling of Native Mitral Valve Physiology: A New Standard for Device and Procedure Testing
Mitral valve regurgitation is among the most prevalent valvular heart diseases and increases with age. Percutaneous therapy has emerged for the management of mitral regurgitation in high surgical risk patients. However, the long-term consequences of these interventions are still not fully understood due to their novelty and the difficulty of developing a strategy specific to the patient’s anatomy and/or pathology. To optimize these outcomes, an in vitro patient-specific approach could provide important insights for the most suitable strategy to use according to the patient profile. To ensure the reliability of this in vitro approach, the aim of this study was to reproduce the physiological behavior of the healthy native mitral valve for future applications. To do so, different silicon combinations reproducing the physiological anatomy of a healthy mitral valve were developed and tested under physiological hemodynamic conditions in a cardiac simulator. The hemodynamic and biomechanical behaviors of each mitral valve model were analyzed and compared to the physiological values provided in the literature. This study identified EcoFlex 00-50 and DragonSkin 10 (Smooth-On Inc., Easton, PA, USA) as the optimal silicon combination resulting in physiological strain values and hemodynamic parameters. These findings could be useful for future patient-specific applications, helping in the optimization of percutaneous mitral valve therapy.
- Open Access
- 25 February 2025
- Published by MDPI AG in Preprints.org
Advanced Silicon Modelling of Native Mitral Valve Physiology: A New Standard for Device and Procedure Testing
Mitral valve regurgitation is among the most prevalent valvular heart diseases and increases with age. Percutaneous therapy has emerged for the management of mitral regurgitation in high surgical risk patients. However, long-term consequences of these interventions are still not fully understood due to their novelty and the difficulty to develop a strategy specific to the patient’s anatomy and/or pathology. To optimize these outcomes, an in vitro patient-specific approach could provide important insights for the most suitable strategy to use according to the patient profile. To ensure reliability of this in vitro approach, aim of this study was to reproduce the physiological behavior of the healthy native mitral valve for future applications. To do so, different silicon combinations reproducing physiological anatomy of healthy mitral valve were developed and tested under physiological hemodynamic conditions in a cardiac simulator. The hemodynamic and biomechanical behaviors of each mitral valve model were analyzed and compared to the physiological values provided in the literature. This study identified EcoFlex 00-50 and DragonSkin 10 (Smooth-On Inc, USA) as the optimal silicon combination resulting in physiological strain values and hemodynamic parameters. These findings could be useful for future patient-specific applications, helping in the optimization of percutaneous mitral valve therapy.
- 25 February 2025
- Published by MDPI AG in Preprints.org
Open AccessAdvanced Silicon Modelling of Native Mitral Valve Physiology: A New Standard for Device and Procedure Testing
Mitral valve regurgitation is among the most prevalent valvular heart diseases and increases with age. Percutaneous therapy has emerged for the management of mitral regurgitation in high surgical risk patients. However, long-term consequences of these interventions are still not fully understood due to their novelty and the difficulty to develop a strategy specific to the patient’s anatomy and/or pathology. To optimize these outcomes, an in vitro patient-specific approach could provide important insights for the most suitable strategy to use according to the patient profile. To ensure reliability of this in vitro approach, aim of this study was to reproduce the physiological behavior of the healthy native mitral valve for future applications. To do so, different silicon combinations reproducing physiological anatomy of healthy mitral valve were developed and tested under physiological hemodynamic conditions in a cardiac simulator. The hemodynamic and biomechanical behaviors of each mitral valve model were analyzed and compared to the physiological values provided in the literature. This study identified EcoFlex 00-50 and DragonSkin 10 (Smooth-On Inc, USA) as the optimal silicon combination resulting in physiological strain values and hemodynamic parameters. These findings could be useful for future patient-specific applications, helping in the optimization of percutaneous mitral valve therapy.